CVS Health Analyst Ratings and Price Targets: A Comprehensive Breakdown

CVS Health's analyst ratings vary from bullish to bearish, with 6 analysts providing insights. Recent ratings show 1 bullish, 4 somewhat bullish, and 1 indifferent. Analysts have raised price targets, with an average of $78.33, a high of $82.00, and a low of $67.00, marking a 2.84% increase from the previous average.

CVS Health (NYSE: CVS) has seen a diverse range of analyst ratings in recent months, reflecting varying opinions on the company's performance and future prospects. As of July 2025, six analysts have provided insights into the pharmaceutical giant, with a mix of bullish, somewhat bullish, and indifferent ratings.

Recent ratings show 1 bullish, 4 somewhat bullish, and 1 indifferent analyst. This distribution indicates a general optimism about the company's potential, but also a cautious stance from some analysts. The bullish ratings are particularly notable, with several analysts raising their price targets and improving their ratings.

The analysts' evaluations of 12-month price targets offer additional insights. The average target of $78.33, with a high estimate of $82.00 and a low of $67.00, marks a 2.84% increase from the previous average of $76.17. This upward trend suggests that analysts are increasingly confident in CVS Health's ability to drive growth and profitability.

Key analysts have recently adjusted their ratings and price targets. For instance, Michael Ha from Baird raised his rating to "Outperform" with a price target of $82.00, up from $71.00. Similarly, Erin Wright from Morgan Stanley raised her rating to "Overweight" with a price target of $82.00, up from $80.00. On the other hand, Kevin Caliendo from UBS lowered his rating to "Neutral" with a price target of $67.00, down from $71.00.

These changes highlight the evolving sentiments among analysts regarding CVS Health. The company's recent earnings report, which showed an EPS of $1.81 and a revenue of $98.92 billion, has likely contributed to the upward revision in price targets. Additionally, the company's strategic acquisitions, such as Oak Street Health, may have influenced analysts' perceptions of its growth potential.

Institutional investors have also shown confidence in CVS Health, with Nuveen LLC acquiring approximately 3 million shares valued at around $204.42 million, representing 0.24% of the company's stock. This significant investment underscores the market's belief in CVS Health's long-term prospects.

Despite the generally positive sentiment, it is essential to consider the mixed ratings and price targets. Analysts' evaluations can vary significantly, and their predictions may not always align with actual market performance. Therefore, investors should remain vigilant and consider multiple factors when making investment decisions.

References:
[1] https://www.benzinga.com/insights/analyst-ratings/25/08/47121147/assessing-cvs-health-insights-from-6-financial-analysts
[2] https://www.marketbeat.com/instant-alerts/filing-nuveen-llc-invests-20442-million-in-cvs-health-corporation-nysecvs-2025-08-12/